Sanofi and Earendil Labs have announced a strategic collaboration effort that goes on to apply the discovery platform from Earendil across many of the Sanofi autoimmune and inflammatory disease programs.
The two AI-powered research and development platforms from Earendil Labs concerning protein therapeutics go on to include both the Foundational Protein AI Platform along with the High-Throughput Biology Platform, respectively. The company confirms that it makes use of these platforms in order to generate some high-quality sequences, forecast the antibody properties, and also validate discoveries by way of experiments. The platform possesses the capability to self-improve.
The CEO of Earendil Labs, Jian Peng, PhD, opines that partnering along with Sanofi enables them to apply the discovery platform by Earendil to a much wider set of autoimmune disease objectives than in the past. Through mixing the advanced predictive protein modeling along with high-throughput experimental validation, they can actually go ahead and identify as well as optimize bispecific antibody candidates in a more efficient and accurate way. This collaboration highlights their commitment to advancing the next-generation therapeutics, which have the potential to set new benchmarks of care.
It is worth noting that autoimmune disease, which is a condition in which the immune system of the body mistakes its own healthy tissues as being foreign and attacks them, can go ahead and cause inflammation, thereby affecting numerous parts of the body. These particular parts of the body that are affected can depend on which kind of autoimmune disease a patient happens to be dealing with. Common signs and symptoms of autoimmune disease go on to include fever, fatigue, muscle aches, and joint pain, as well as skin problems, swelling, along with abdominal pain, digestion problems, and also swollen glands. This partnership marks the second time that Sanofi and Earendil have collaborated on autoimmune as well as inflammatory diseases. It was back in April 2025 that both had entered a $1.7 billion exclusive license agreement when it came to two potential first-in-class bispecific antibodies – the HXN-1002 and HXN-1003.
The president & co-CEO of Earendil Labs, Zhenping Zhu, MD, PhD, went on to discuss the significance of Earendil and Sanofi’s first license agreement and its emphasis on the autoimmune disease treatments, stating that autoimmune diseases that go on to affect millions of patients get characterized by way of chronic disease processes as well as relapse rates that are high. These diseases more often than not need lifelong treatment, thereby severely affecting the quality of life of patients and prominently increasing the societal burden.
According to the terms of the collaboration agreement, Sanofi is anticipated to lead both development and the global commercialization of bispecific candidates that crop up from the collaboration effort.
The overall potential value when it comes to this collaboration agreement is valued at over $2.5 billion, including the upfront and development costs as well as commercial milestones. As part of this collaboration agreement, Earendil is going to receive almost $160 million in terms of upfront and near-term payments, which are tied to early program accomplishments.
Zhenping Zhu went on to touch on the probable abilities that this collaboration is going to enable when it comes to researching as well as discovering the autoimmune disease treatments, remarking that the autoimmune diseases impose quite a heavy burden when it comes to patients along with healthcare systems, with many conditions needing lifelong management and also often giving out incomplete responses to the present therapies. Through making utmost use of the deep expertise of Sanofi when it comes to clinical development along with global commercialization, they look forward to speeding up the translation of their platform-enabled bispecific antibody candidates within the potentially transformative medicines, therefore bringing the new treatment alternatives to patients who are actually in need.
